{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "147",
  "slug": "drug-discovery-back-to-the-bench",
  "edition": "2026-10-17T00",
  "url": "https://hangingcontext.com/stories/2026-10-17/drug-discovery-back-to-the-bench/",
  "newsroom": "health-biotech",
  "beat": null,
  "newsroom_title": "Health & Biotech",
  "angle": "Drug discovery's wet-lab week: new binding pockets, resurrected gene relics, and novel chemotypes from synthesis and genome mining.",
  "headline": "Drug discovery goes back to the bench: new pockets, new agonists, new chemistry",
  "dek": "Researchers built bird-receptor agonists from an extinct ostrich gene relic, drugged a hidden pocket on the angiogenesis regulator RhoJ, advanced a selective epilepsy compound that pairs with CBD, and reported new antimalarial and antitumor chemotypes.",
  "published_at": "2026-10-17T00:28:14Z",
  "labels": {
    "trust": "reported",
    "trust_text": "Reported · 5 sources",
    "newsroom": "Health & Biotech"
  },
  "source_count": 5,
  "publishers": [
    "biorxiv-protein-structure-drug-discovery",
    "chemrxiv-drug-discovery-medicinal-chemistry"
  ],
  "key_facts": [
    {
      "text": "A 22-residue C-terminal fragment from an ostrich CXCL17 gene relic, grafted onto human or turtle CXCL17, creates potent avian GPR25 agonists; the C-terminus drives species selectivity, and the hybrids reach 5-13 nM potency at the mallard GPR25 receptor.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1792183937290524673",
          "claim_ids": [
            "1792184174665208484",
            "1792184174669908757",
            "1792184174675773990"
          ]
        }
      ]
    },
    {
      "text": "RhoJ carries a unique N-terminal extension (Asn2-Lys19) absent in Cdc42 and other Rho GTPases; the antifungal terconazole occupies this pocket and disrupts the RhoJ:PAK3 interaction in a dose-dependent manner, and an eBRET2 biosensor validates live-cell monitoring of the interaction.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1792183937290492293",
          "claim_ids": [
            "1792184177781255236",
            "1792184177789143394",
            "1792184177808824035"
          ]
        }
      ]
    },
    {
      "text": "GAT1508 selectively activates neuronal GIRK1/2 heterotetramers with superior antiseizure efficacy in PTZ-induced seizure models versus ML297 and GiGA1, spares cardiac GIRK1/4 channels, and synergizes with cannabidiol in hippocampal slices and in vivo models.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1792183937290261963",
          "claim_ids": [
            "1792184175701701618",
            "1792184175703925220",
            "1792184175705324740",
            "1792184175707867044"
          ]
        }
      ]
    },
    {
      "text": "In 3H-1,5-benzodiazepine derivatives, compound 5o shows anti-plasmodial IC50 values of 5.88 µM against PfD10 and 6.68 µM against PfW2, compounds 5k and 5n show favorable HepG2 selectivity, and computational analysis points to PfSET3 as a potential target.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1792170632836437412",
          "claim_ids": [
            "1792170948153950018",
            "1792170948155094736",
            "1792170948157003880"
          ]
        }
      ]
    },
    {
      "text": "Genome mining of Fusarium sp. WA57 uncovered fusariolones A-E and semifusariolone A, a distinct family of fungal polyketide-tropolone hybrids; the fusABCDEF gene set is the minimal biosynthetic pathway, and fusariolone A shows low-nanomolar antiproliferative activity selective for K562 and HT-29 cells.",
      "self_reported": true,
      "cites": [
        {
          "manifest_id": "1792142948899302357",
          "claim_ids": [
            "1792143969007572716",
            "1792143969041298767",
            "1792143969050201754"
          ]
        }
      ]
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "A new pocket on a tumor angiogenesis regulator",
      "paragraphs": [
        {
          "markdown": "In a preprint posted to bioRxiv this week, researchers identified a unique N-terminal extension (Asn2-Lys19) on RhoJ, a Rho GTPase that regulates tumor angiogenesis, that is absent in Cdc42 and other Rho GTPases. That difference is the whole point: pockets shared across a protein family are hard to drug selectively, while a pocket that exists only on RhoJ offers a path to selective anti-angiogenic compounds.",
          "cites": [
            {
              "manifest_id": "1792183937290492293",
              "claim_ids": [
                "1792184177781255236"
              ]
            }
          ]
        },
        {
          "markdown": "The team validated the pocket with the antifungal terconazole, which occupies the RhoJ N-terminal pocket and disrupts the RhoJ:PAK3 signaling interaction in a dose-dependent manner. They also built an eBRET2-based biosensor that provides a validated platform for monitoring the RhoJ:PAK3 interaction in live cells, which gives any follow-on screening campaign a ready-made readout.",
          "cites": [
            {
              "manifest_id": "1792183937290492293",
              "claim_ids": [
                "1792184177789143394",
                "1792184177808824035"
              ]
            }
          ]
        },
        {
          "markdown": "This suggests a broader lesson about where first-in-class chemistry comes from: not a better model of a known pocket, but a pocket nobody knew existed. RhoJ's N-terminal extension is the kind of target that only surfaces when structural biology is pointed at the parts of a protein family the textbooks treat as unremarkable.",
          "cites": [
            {
              "manifest_id": "1792183937290492293",
              "claim_ids": [
                "1792184177781255236",
                "1792184177789143394"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "An agonist resurrected from an extinct gene",
      "paragraphs": [
        {
          "markdown": "Another preprint took a more unusual starting material: a gene relic. Researchers grafted a 22-residue C-terminal fragment from an ostrich CXCL17 gene relic onto human or turtle CXCL17 and found that the fragment confers potent agonism to avian GPR25, with the C-terminus acting as the primary driver of species selectivity for GPR25 activation.",
          "cites": [
            {
              "manifest_id": "1792183937290524673",
              "claim_ids": [
                "1792184174665208484",
                "1792184174669908757"
              ]
            }
          ]
        },
        {
          "markdown": "The resulting turtle-ostrich and human-ostrich CXCL17 hybrids exhibit 5-13 nM potency at the mallard GPR25 receptor. The result is a proof of concept that functional protein fragments can be recovered from gene relics to engineer potent receptor agonists, which suggests that extinct or pseudogenized sequences are a largely untapped library of starting material for ligand engineering.",
          "cites": [
            {
              "manifest_id": "1792183937290524673",
              "claim_ids": [
                "1792184174675773990"
              ]
            }
          ]
        },
        {
          "markdown": "The relic-mining angle generalizes. Genomes carry pseudogenized fragments that were once functional proteins, and this paper demonstrates they can be resurrected into potent ligands. This suggests extinct sequences could become a systematic source of novel protein fragments for receptor pharmacology, with the caveat that each fragment has to be shown to fold and behave as it did in its original context.",
          "cites": [
            {
              "manifest_id": "1792183937290524673",
              "claim_ids": [
                "1792184174665208484",
                "1792184174675773990"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "A safer antiseizure scaffold that pairs with CBD",
      "paragraphs": [
        {
          "markdown": "In epilepsy, the compound GAT1508 is presented as a selective activator of neuronal GIRK1/2 heterotetramers that exhibits superior antiseizure efficacy in PTZ-induced seizure models compared to the earlier tools ML297 and GiGA1.",
          "cites": [
            {
              "manifest_id": "1792183937290261963",
              "claim_ids": [
                "1792184175701701618",
                "1792184175703925220"
              ]
            }
          ]
        },
        {
          "markdown": "Two properties make it translationally interesting. First, GAT1508 does not significantly activate cardiac GIRK1/4 channels, suggesting reduced cardiovascular risk, which has been the major safety hurdle for GIRK-targeted epilepsy therapies. Second, it synergizes with cannabidiol to potentiate antiseizure effects in hippocampal slice recordings and in vivo models, opening a combination path for refractory epilepsy.",
          "cites": [
            {
              "manifest_id": "1792183937290261963",
              "claim_ids": [
                "1792184175705324740",
                "1792184175707867044"
              ]
            }
          ]
        },
        {
          "markdown": "The CBD synergy matters practically as well as scientifically: cannabidiol is already used in some epilepsy syndromes, so a compound that potentiates it has a clearer clinical path than a monotherapy with unknown drug interactions. The selectivity over cardiac channels is the piece that makes that path worth walking.",
          "cites": [
            {
              "manifest_id": "1792183937290261963",
              "claim_ids": [
                "1792184175705324740",
                "1792184175707867044"
              ]
            }
          ]
        }
      ]
    },
    {
      "heading": "New chemotypes against malaria and tumors",
      "paragraphs": [
        {
          "markdown": "In a ChemRxiv preprint, 3H-1,5-benzodiazepine derivatives were evaluated against P. falciparum strains: compound 5o showed anti-plasmodial activity with IC50 values of 5.88 µM against PfD10 and 6.68 µM against PfW2, while compounds 5k and 5n demonstrated favorable selectivity profiles against HepG2 cells relative to the other derivatives.",
          "cites": [
            {
              "manifest_id": "1792170632836437412",
              "claim_ids": [
                "1792170948153950018",
                "1792170948155094736"
              ]
            }
          ]
        },
        {
          "markdown": "Computational analysis, including MM-GBSA and molecular dynamics simulations, identifies PfSET3 as a potential target for the scaffold, giving the chemistry a testable hypothesis to carry into the next round of optimization.",
          "cites": [
            {
              "manifest_id": "1792170632836437412",
              "claim_ids": [
                "1792170948157003880"
              ]
            }
          ]
        },
        {
          "markdown": "Finally, genome mining of Fusarium sp. WA57 yielded fusariolones A-E and semifusariolone A, a distinct family of fungal polyketide-tropolone hybrids. The researchers defined the fusABCDEF gene set as the minimal biosynthetic pathway for the scaffold, and fusariolone A exhibits low-nanomolar antiproliferative activity with selectivity toward K562 and HT-29 cells, making it a credible lead for oncology development.",
          "cites": [
            {
              "manifest_id": "1792142948899302357",
              "claim_ids": [
                "1792143969007572716",
                "1792143969041298767",
                "1792143969050201754"
              ]
            }
          ]
        }
      ]
    }
  ],
  "unresolved": [
    "All five studies are preprints and have not completed peer review.",
    "Terconazole's RhoJ activity is a starting point, not a drug; lead optimization for potency and selectivity is unreported.",
    "GAT1508's safety advantage rests on preclinical models; human cardiac liability is untested.",
    "The antimalarial and fusariolone activities are early-stage; in vivo efficacy and toxicity data are pending."
  ],
  "decision_card": {
    "useful_for": [
      "Biotech investors scouting first-in-class target and chemotype opportunities",
      "Medicinal chemists and drug-hunters tracking new screening pockets and scaffolds"
    ],
    "not_for": [
      "Investors seeking clinical-stage assets; all findings here are discovery-stage preprints"
    ],
    "compare_against": [
      "AI-first virtual screening and de novo design platforms in the same indications"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "edition-2026-10-17T00-batch5"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1792183937290524673",
    "1792183937290492293",
    "1792183937290261963",
    "1792170632836437412",
    "1792142948899302357"
  ],
  "manifests": [
    {
      "manifest_id": "1792183937290524673",
      "title": "Engineering potent avian GPR25 agonists using an ostrich CXCL17 gene relic",
      "source_name": "biorxiv-protein-structure-drug-discovery",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.14.759250v1.full",
      "published_date": "2026-10-16"
    },
    {
      "manifest_id": "1792183937290492293",
      "title": "Identification and targeting of a novel drug pocket in the tumour angiogenesis regulator RhoJ",
      "source_name": "biorxiv-protein-structure-drug-discovery",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.14.758331v1.full",
      "published_date": "2026-10-16"
    },
    {
      "manifest_id": "1792183937290261963",
      "title": "GAT1508, a selective neuronal GIRK1/2 activator, exhibits superior antiepileptic efficacy and synergizes with cannabidiol",
      "source_name": "biorxiv-protein-structure-drug-discovery",
      "source_url": "https://biorxiv.org/content/10.64898/2026.10.14.758970v1.full",
      "published_date": "2026-10-16"
    },
    {
      "manifest_id": "1792170632836437412",
      "title": "3H-1,5-Benzodiazepine Derivatives as Novel Antimalarial Agents: Synthesis, Biological Evaluation and Computational Target Exploration",
      "source_name": "chemrxiv-drug-discovery-medicinal-chemistry",
      "source_url": "https://chemrxiv.org/doi/full/10.26434/chemrxiv.15010605/v1",
      "published_date": "2026-10-16"
    },
    {
      "manifest_id": "1792142948899302357",
      "title": "Genome Mining-Guided Discovery of Polyketide-Tropolone Hybrids Reveals Their Biosynthetic Logic and Antitumor Activity",
      "source_name": "chemrxiv-drug-discovery-medicinal-chemistry",
      "source_url": "https://chemrxiv.org/doi/full/10.26434/chemrxiv.15010572/v1",
      "published_date": "2026-10-16"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1792183937290524673",
      "1792183937290492293",
      "1792183937290261963",
      "1792170632836437412",
      "1792142948899302357"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; 3 of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1792183937290524673",
      "all": "for id in 1792183937290524673 1792183937290492293 1792183937290261963 1792170632836437412 1792142948899302357; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-10-17/drug-discovery-back-to-the-bench/",
    "json": "https://hangingcontext.com/stories/2026-10-17/drug-discovery-back-to-the-bench/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-10-17/drug-discovery-back-to-the-bench/index.md",
    "newsroom": "https://hangingcontext.com/n/health-biotech/",
    "edition": "https://hangingcontext.com/editions/2026-10-17T00/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-10-17/immune-metabolism-cancer-therapy/",
      "headline": "Cancer's immune-metabolism levers: how tumors suppress immunity, and what fights back",
      "slug": "immune-metabolism-cancer-therapy"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Run the cited Manifests yourself",
    "text": "Every claim in this paper points to a Manifest id. Get a Synorb Key and read the Manifests behind it. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; 3 of them are starter Beacons.",
    "cta": {
      "label": "Get a key",
      "url": "https://synorb.com/connect"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-10-17/drug-discovery-back-to-the-bench/"
  }
}